Search

Your search keyword '"Nathalie Maitre"' showing total 13 results
Start Over Author "Nathalie Maitre" Search Limiters Full Text
13 results on '"Nathalie Maitre"'

1. Integrating neuroimaging biomarkers into the multicentre, high-dose erythropoietin for asphyxia and encephalopathy (HEAL) trial: rationale, protocol and harmonisation

Author

Taeun Chang, Brenda Poindexter, Gregory M. Sokol, Patrick J Heagerty, Mark Smith, Jessica L Wisnowski, Amit M Mathur, Jeffrey Berman, Ping-Sun Keven Chen, James Dix, Trevor Flynn, Stanley Fricke, Seth D Friedman, Hayden W Head, Chang Y Ho, Beth Kline-Fath, Michael Oveson, Richard Patterson, Sumit Pruthi, Nancy Rollins, Yanerys M Ramos, John Rampton, Jerome Rusin, Dennis W Shaw, Jean Tkach, Shreyas Vasanawala, Arastoo Vossough, Matthew T Whitehead, Duan Xu, Kristen Yeom, Bryan Comstock, Sandra E Juul, Yvonne W Wu, Robert C McKinstry, Kaashif Ahmed, Mariana Beserga, Ellen Bendel-Stenzel, Lina Chalak, John Flibotte, Fernando Gonzalez, Andrea Lampland, Nathalie Maitre, Amit M. Mathur, Dennis Mayock, Ulrike Mietzsch, Rakesh Rao, David Riley, Krisa Van Meurs, Hendrik Weitkamp, Tai-Wei Wu, and Toby Yanowitz

Subjects
Medicine
Abstract

Introduction MRI and MR spectroscopy (MRS) provide early biomarkers of brain injury and treatment response in neonates with hypoxic-ischaemic encephalopathy). Still, there are challenges to incorporating neuroimaging biomarkers into multisite randomised controlled trials. In this paper, we provide the rationale for incorporating MRI and MRS biomarkers into the multisite, phase III high-dose erythropoietin for asphyxia and encephalopathy (HEAL) Trial, the MRI/S protocol and describe the strategies used for harmonisation across multiple MRI platforms.Methods and analysis Neonates with moderate or severe encephalopathy enrolled in the multisite HEAL trial undergo MRI and MRS between 96 and 144 hours of age using standardised neuroimaging protocols. MRI and MRS data are processed centrally and used to determine a brain injury score and quantitative measures of lactate and n-acetylaspartate. Harmonisation is achieved through standardisation—thereby reducing intrasite and intersite variance, real-time quality assurance monitoring and phantom scans.Ethics and dissemination IRB approval was obtained at each participating site and written consent obtained from parents prior to participation in HEAL. Additional oversight is provided by an National Institutes of Health-appointed data safety monitoring board and medical monitor.Trial registration number NCT02811263; Pre-result.

Published
2021
Full Text
View/download PDF

2. Impact of the Coronavirus Pandemic on High-Risk Infant Follow-Up (HRIF) Programs: A Survey of Academic Programs

Author

Sanjeet Panda, Rashmi Somu, Nathalie Maitre, Garrett Levin, and Ajay Pratap Singh

Subjects
High Risk Infant Follow-Up (HRIF) Clinic, telemedicine, early childhood development, neonates, preterm neonates, coronavirus, Pediatrics, RJ1-570
Abstract

Objective: The impact of the COVID-19 pandemic on the functioning and services of academic high-risk infant follow-up (HRIF) clinics throughout North America. Study Design: Prospective 25-question questionnaire survey through REDCAP links that was sent over 10 weeks, to 105 US and 10 Canadian programs. Finally, 59 of 105 US programs and 5 of 10 Canadian responses were analyzed using SAS version 9.4. Results: In the US, 67% of programs reported closures between 1–5 months, whereas in Canada 80% of programs closed for 1–3 months. In the US 86% of programs provided telemedicine visits and only 42.5% provided multidisciplinary HRIF telemedicine visits. We enumerated innovative approaches specifically for the conduct of Telemedicine visits, the need for the standardization of various tests and services in a telemedicine setting, and to emphasize the urgent need for more government funding to improve follow-up and developmental services to this fragile group of newborns.

Published
2021
Full Text
View/download PDF

3. Risk of seizures in neonates with hypoxic-ischemic encephalopathy receiving hypothermia plus erythropoietin or placebo

Author

Hannah C. Glass, Courtney J. Wusthoff, Bryan A. Comstock, Adam L. Numis, Fernando F. Gonzalez, Nathalie Maitre, Shavonne L. Massey, Dennis E. Mayock, Ulrike Mietzsch, Niranjana Natarajan, Gregory M. Sokol, Sonia L. Bonifacio, Krisa P. Van Meurs, Cameron Thomas, Kaashif A. Ahmad, Patrick J. Heagerty, Sandra E. Juul, and Yvonne W. Wu

Subjects
Pediatrics, Perinatology and Child Health
Published
2022

5. Correction: The american pediatric society and society for pediatric research joint statement against racism and social injustice

Author

Steven H. Abman, Sarah Armstrong, Susan Baker, Clifford W. Bogue, Waldemar Carlo, Lina Chalak, Stephen R. Daniels, Stephanie Davis, Michael R. Debaun, Candice Fike, Lauren Frazer, Keisha Gibson, Michelle Gill, Hannah Glass, Catherine M. Gordon, Monika Goyal, Joel Hirschhorn, Lori Holtz, David A. Hunstad, Mary B. Leonard, Nathalie Maitre, Larry Markham, Linda McAllister-Lucas, Jordan Orange, Prachi Shah, Tamara Simon, Robin H. Steinhorn, Beth Tarini, and Leslie R. Walker-Harding

Subjects
Pediatrics, Perinatology and Child Health
Published
2021

6. Acute Responses to Diuretic Therapy in Extremely Low Gestational Age Newborns: Results from the Prematurity and Respiratory Outcomes Program Cohort Study

Author

Carol J. Blaisdell, James Troendle, Anne Zajicek, Claire Chougnet, James M. Greenberg, William Hardie, Alan H. Jobe, Karen McDowell, Thomas Ferkol, Mark R. Holland, James Kemp, Philip T. Levy, Phillip Tarr, Gautam K. Singh, Barbara Warner, Aaron Hamvas, Philip L. Ballard, Roberta A. Ballard, Roberta L. Keller, Amir M. Khan, Leslie Lusk, Dennis W. Nielson, Elizabeth E. Rogers, David J. Durand, Jeffrey D. Merrill, Eric C. Eichenwald, Candice Fike, Tina Hartert, Paul Moore, Judy Aschner, Scott Guthrie, Nathalie Maitre, Marshall Summar, Carl D'Angio, Vasanth Kumar, Tom Mariani, Gloria Pryhuber, Anne Marie Reynolds, Kristin Scheible, Timothy Stevens, Clement Ren, Rita M. Ryan, C. Michael Cotten, Kim Fisher, Jack Sharp, Judith A. Voynow, Stephanie Davis, Brenda Poindexter, Jonas Ellenberg, Rui Feng, Melissa Fernando, Howard Panitch, Barbara Schmidt, Pamela Shaw, Scarlett Bellamy, and Lynn M. Taussig

Subjects
Male, Pediatrics, medicine.medical_specialty, Neonatal intensive care unit, medicine.medical_treatment, Birth weight, Gestational Age, Article, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, 030225 pediatrics, Intensive care, Intensive Care Units, Neonatal, Medicine, Humans, 030212 general & internal medicine, Airway Management, Diuretics, Respiratory Distress Syndrome, Newborn, Respiratory distress, business.industry, Respiration, Postmenstrual Age, Infant, Newborn, Gestational age, United States, Infant, Extremely Premature, Pediatrics, Perinatology and Child Health, Female, Diuretic, business, Cohort study
Abstract

OBJECTIVE: To determine if daily respiratory status improved more in extremely low gestational age premature infants after diuretic exposure compared with those not exposed in modern neonatal intensive care units (NICU). STUDY DESIGN: The Prematurity and Respiratory Outcomes Program (PROP) was a multi-center observational cohort study of 835 extremely premature infants, gestational ages 23 0/7–28 6/7 weeks, enrolled in the first week of life from 13 U.S. tertiary NICUs. We analyzed the PROP study daily medication and respiratory support records of infants up to 34 weeks postmenstrual age. We determined whether there was a temporal association between administration of diuretics and an acute change in respiratory status in premature infants in the NICU, using an ordered categorical ranking of respiratory status. RESULTS: Infants in the diuretic exposed group of PROP were of lower mean gestational age and lower mean birth weight (p 1) for each day after the initial day of diuretic exposure. CONCLUSIONS: Our analysis did not support the ability of diuretics to substantially improve the extremely premature infant’s respiratory status. Further study of both safety and efficacy of diuretics in this setting are warranted. TRIAL REGISTRATION: Clinicaltrials.gov NCT01435187

Published
2017

7. Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium

Author

Rita M. Ryan, Roberta L. Keller, Brenda B. Poindexter, Carl T. D'Angio, Pamela A. Shaw, Scarlett L. Bellamy, Paul E. Moore, Christopher McPherson, James M. Greenberg, Barbara Alexander, Tari Gratton, Cathy Grigsby, Beth Koch, Kelly Thornton, Pamela Bates, Claudia Cleveland, Julie Hoffmann, Laura Linneman, Jayne Sicard-Su, Gina Simpson, Jeanette M. Asselin, Samantha Balan, Katrina Burson, Cheryl Chapin, Erna Josiah-Davis, Carmen Garcia, Hart Horneman, Rick Hinojosa, Christopher Johnson, Susan Kelley, Karin L. Knowles, M. Layne Lillie, Karen Martin, Sarah Martin, Julie Arldt-McAlister, Georgia E. McDavid, Lori Pacello, Shawna Rodgers, Daniel K. Sperry, Amy B. Beller, Mark O’ Hunt, Theresa J. Rogers, Odessa L. Settles, Steven Steele, Sharon Wadley, Shannon Castiglione, Aimee Horan, Deanna Maffet, Jane O'Donnell, Michael Sacilowski, Tanya Scalise, Elizabeth Werner, Jason Zayac, Heidie Huyck, Valerie Lunger, Kim Bordeaux, Pam Brown, Julia Epping, Lisa Flattery-Walsh, Donna Germuga, Nancy Jenks, Mary Platt, Eileen Popplewell, Sandra Prentice, Kim Ciccio, Charles Clem, Susan Gunn, Lauren Jewett, Maria Blanco, Denise Cifelli, Sara DeMauro, Melissa Fernando, Ann Tierney, Lynn M. Taussig, Carol J. Blaisdell, Claire Chougnet, William Hardie, Alan H. Jobe, Karen McDowell, Thomas Ferkol, Aaron Hamvas, Mark R. Holland, James Kemp, Philip T. Levy, Phillip Tarr, Gautam K. Singh, Barbara Warner, Philip L. Ballard, Roberta A. Ballard, David J. Durand, Eric C. Eichenwald, Amir M. Khan, Leslie Lusk, Jeffrey D. Merrill, Dennis W. Nielson, Elizabeth E. Rogers, Judy Aschner, Candice Fike, Scott Guthrie, Tina Hartert, Nathalie Maitre, Marshall Summar, Vasanth Kumar, Tom Mariani, Gloria Pryhuber, Clement Ren, Anne Marie Reynolds, Kristin Scheible, Timothy Stevens, C. Michael Cotten, Kim Fisher, Jack Sharp, Judith A. Voynow, Stephanie Davis, Jonas Ellenberg, Rui Feng, Howard Panitch, and Barbara Schmidt

Subjects
Male, Pediatrics, medicine.medical_specialty, Neonatal intensive care unit, medicine.drug_class, medicine.medical_treatment, Anti-Inflammatory Agents, Gestational Age, Infant, Premature, Diseases, Article, 03 medical and health sciences, 0302 clinical medicine, Prednisone, Intensive Care Units, Neonatal, Surveys and Questionnaires, 030225 pediatrics, Bronchodilator, Administration, Inhalation, medicine, Humans, Prospective Studies, 030212 general & internal medicine, Respiratory system, Diuretics, Prospective cohort study, Bronchopulmonary Dysplasia, business.industry, Infant, Newborn, Infant, Gestational age, medicine.disease, Patient Discharge, Bronchodilator Agents, Oxygen, Treatment Outcome, Bronchopulmonary dysplasia, Pediatrics, Perinatology and Child Health, Female, Steroids, Diuretic, business, Infant, Premature, medicine.drug
Abstract

OBJECTIVE: To determine patterns of respiratory medications used in neonatal intensive care unit (NICU) graduates. STUDY DESIGN: The Prematurity Respiratory Outcomes Program enrolled 835 babies

Published
2019

8. Black Race Is Associated with a Lower Risk of Bronchopulmonary Dysplasia

Author

Rita M. Ryan, Rui Feng, Catalina Bazacliu, Thomas W. Ferkol, Clement L. Ren, Thomas J. Mariani, Brenda B. Poindexter, Fan Wang, Paul E. Moore, Claire Chougnet, James M. Greenberg, William Hardie, Alan H. Jobe, Karen McDowell, Aaron Hamvas, Mark R. Holland, James Kemp, Philip T. Levy, Christopher McPherson, Phillip Tarr, Gautam K. Singh, Barbara Warner, Philip L. Ballard, Roberta A. Ballard, David J. Durand, Eric C. Eichenwald, Amir M. Khan, Leslie Lusk, Jeffrey D. Merrill, Dennis W. Nielson, Elizabeth E. Rogers, Judy Aschner, Candice Fike, Scott Guthrie, Tina Hartert, Nathalie Maitre, Marshall Summar, Carl T. D'Angio, Vasanth Kumar, Gloria Pryhuber, Anne Marie Reynolds, Kristin Scheible, Timothy Stevens, C. Michael Cotten, Kim Fisher, Jack Sharp, Judith A. Voynow, Stephanie Davis, Scarlett A. Bellamy, Jonas Ellenberg, Melissa Fernando, Howard Panitch, Pamela A. Shaw, Barbara Schmidt, Lynn M. Taussig, and Carol J. Blaisdell

Subjects
Pediatrics, medicine.medical_specialty, Gestational Age, Infant, Premature, Diseases, Lower risk, Black race, Risk Assessment, behavioral disciplines and activities, White People, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Intensive Care Units, Neonatal, 030225 pediatrics, mental disorders, medicine, Humans, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, Bronchopulmonary Dysplasia, business.industry, Respiratory disease, Follow up studies, Gestational age, medicine.disease, United States, Large cohort, Black or African American, Hospitalization, Survival Rate, Bronchopulmonary dysplasia, Pediatrics, Perinatology and Child Health, Morbidity, business, Infant, Premature, Follow-Up Studies
Abstract

To use a large current prospective cohort of infants29 weeks to compare bronchopulmonary dysplasia (BPD) rates in black and white infants.The Prematurity and Respiratory Outcome Program (PROP) enrolled 835 infants born in 2011-2013 at29 weeks of gestation; 728 black or white infants survived to 36 weeks postmenstrual age (PMA). Logistic regression was used to compare BPD outcomes (defined as supplemental oxygen requirement at 36 weeks PMA) between the races, adjusted for gestational age (GA), antenatal steroid use, intubation at birth, and surfactant use at birth.Of 707 black or white infants with available BPD outcomes, BPD was lower in black infants (38% vs 45%), even though they were of significantly lower GA. At every GA, BPD was more common in white infants. The aOR for BPD was 0.60 (95% CI, 0.42-0.85; P = .004) for black infants compared with white infants after adjusting for GA. Despite the lower rate of BPD, black infants had a higher rate of first-year post-prematurity respiratory disease (black, 79%; white, 63%).In this large cohort of recently born preterm infants at29 weeks GA, compared with white infants, black infants had a lower risk of BPD but an increased risk of persistent respiratory morbidity.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results